Compare DRTS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRTS | ALVO |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Israel | Luxembourg |
| Employees | 121 | 1460 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 978.2M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | DRTS | ALVO |
|---|---|---|
| Price | $9.73 | $3.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $8.67 | $8.00 |
| AVG Volume (30 Days) | 933.1K | ★ 1.0M |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | $699.98 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $2.94 |
| 52 Week High | $11.62 | $9.94 |
| Indicator | DRTS | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 55.06 |
| Support Level | $6.59 | $3.09 |
| Resistance Level | $11.48 | $4.17 |
| Average True Range (ATR) | 0.83 | 0.32 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 39.92 | 59.39 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.